These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 8575155)

  • 1. Rheumatoid arthritis exacerbation by G-CSF treatment for bucillamine-induced agranulocytosis.
    Nakashima H; Kawabe K; Ohtsuka T; Hayashida K; Horiuchi T; Nagasawa K; Niho Y
    Clin Exp Rheumatol; 1995; 13(5):677-9. PubMed ID: 8575155
    [No Abstract]   [Full Text] [Related]  

  • 2. [A case of rheumatoid arthritis associated with agranulocytosis during bucillamine treatment].
    Negishi M; Yamazaki J; Hosaka M; Iwabuchi H; Matsuda A; Kanemitsu H; Hiramatsu K; Kaga S; Hashimoto M; Kasama T
    Ryumachi; 1994 Jun; 34(3):651-5. PubMed ID: 8052932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperleucocytosis following G-CSF treatment for sulfasalazine-induced agranulocytosis.
    Chan K; Farooq R
    BMJ Case Rep; 2015 Jul; 2015():. PubMed ID: 26178004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Tenoxicam-induced agranulocytosis, with good response to colony stimulating factor (G-CSF)].
    Sánchez Sevillano A; Blázquez Encinar JC; Femenia Pérez M; Mora Rufete MA
    An Med Interna; 1993 Oct; 10(10):519-20. PubMed ID: 7511003
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of drug-induced agranulocytosis with colony stimulating factors (G-CSF or GM-CSF).
    Góra-Tybor J; Krykowski E; Robak T
    Arch Immunol Ther Exp (Warsz); 1996; 44(4):255-8. PubMed ID: 9017166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Bucillamine-associated membranous nephropathy in a patient with rheumatoid arthritis].
    Kawano M; Nomura H; Iwainaka Y; Nakashima A; Koni I; Tofuku Y; Takeda R
    Nihon Jinzo Gakkai Shi; 1990 Jul; 32(7):817-21. PubMed ID: 2273598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Hematopoietic growth factors as supportive treatment in drug-induced agranulocytosis].
    Hospers GA; de Wolf JT; Hazenberg BP; Vellenga E
    Ned Tijdschr Geneeskd; 1993 Oct; 137(42):2152-4. PubMed ID: 7694163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonchemotherapy drug-induced agranulocytosis in elderly patients: the effects of granulocyte colony-stimulating factor.
    Andrès E; Kurtz JE; Martin-Hunyadi C; Kaltenbach G; Alt M; Weber JC; Sibilia J; Schlienger JL; Dufour P; Maloisel Fr
    Am J Med; 2002 Apr; 112(6):460-4. PubMed ID: 11959056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bucillamine-induced pemphigus vulgaris.
    Yanagishita T; Tamada Y; Watanabe D
    J Eur Acad Dermatol Venereol; 2015 Jun; 29(6):1242-3. PubMed ID: 24641261
    [No Abstract]   [Full Text] [Related]  

  • 10. Yellow nails under bucillamine therapy for rheumatoid arthritis: a report of two cases.
    Yamamoto T; Yokozeki H
    Rheumatol Int; 2007 Apr; 27(6):603-4. PubMed ID: 17103174
    [No Abstract]   [Full Text] [Related]  

  • 11. [Lung injury associated with bucillamine therapy].
    Negishi M; Kaga S; Kasama T; Hashimoto M; Fukushima T; Yamagata N; Tabata M; Kobayashi K; Ide H; Takahashi T
    Ryumachi; 1992 Apr; 32(2):135-9. PubMed ID: 1595005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sulfasalazine induced agranulocytosis treated with granulocyte-macrophage colony stimulating factor.
    Kuipers EJ; Vellenga E; de Wolf JT; Hazenberg BP
    J Rheumatol; 1992 Apr; 19(4):621-2. PubMed ID: 1350640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunopharmacological evaluation of bucillamine in rheumatoid arthritis.
    Matsuno H; Kitano T; Matsushita I; Tsuji H; Ochiai H
    Drugs Exp Clin Res; 1993; 19(5):205-11. PubMed ID: 8174492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of clinical effects of bucillamine between additive combination and single administration study in rheumatoid arthritis.
    Nobunaga M; Yasuda M
    Agents Actions Suppl; 1993; 44():105-9. PubMed ID: 8372720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A case of pulmonary infiltration with eosinophilia (PIE) syndrome induced by bucillamine treatment of rheumatoid arthritis].
    Kishimoto N; Fujii K
    Nihon Kokyuki Gakkai Zasshi; 2002 Apr; 40(4):321-5. PubMed ID: 12096503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A case of drug-induced interstitial pneumonitis in rheumatoid arthritis treated with bucillamine].
    Matsushima H; Takayanagi N; Sakamoto T; Motegi M; Ubukata M; Yanagisawa T; Sugita Y; Kanazawa M; Kawabata Y
    Nihon Kokyuki Gakkai Zasshi; 2001 Jan; 39(1):55-9. PubMed ID: 11296388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bucillamine induced pulmonary injury occurs with immunoglobulin decrease.
    Inokuma S; Sakata M; Yoshida A; Shiratori K; Kiyosawa H
    J Rheumatol; 1996 Jul; 23(7):1282-5. PubMed ID: 8823707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Yellow nail induced by bucillamine.
    Ishizaki C; Sueki H; Kohsokabe S; Nishida H
    Int J Dermatol; 1995 Jul; 34(7):493-4. PubMed ID: 7591416
    [No Abstract]   [Full Text] [Related]  

  • 19. [A case of rheumatoid arthritis developing pemphigus-like skin lesion during treatment with bucillamine].
    Amasaki Y; Sagawa A; Atsumi T; Jodo S; Nakabayashi T; Watanabe I; Mukai M; Fujisaku A; Nakagawa S; Kobayashi H
    Ryumachi; 1991 Oct; 31(5):528-34; discussion 531-3. PubMed ID: 1837388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathological findings of bucillamine-induced nephrotic syndrome in patients with rheumatoid arthritis.
    Yoshida A; Morozumi K; Suganuma T; Sugito K; Ikeda M; Oikawa T; Fujinami T; Takeda A; Koyama K
    Am J Nephrol; 1991; 11(4):284-8. PubMed ID: 1799186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.